Pharmacokinetics and acute renal effects of continuously infused carboplatin

Daryl J. Murry, John T. Sandlund, Lisa M. Stricklin, John H. Rodman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Carboplatin was given as a 24‐hour infusion at high doses to pediatric patients with cancer (n = 11) and pharmacokinetic parameters and renal effects were determined. Median carboplatin clearance for course 1 (151 ml/min per 1.73 m2;) was not significantly different from clearance for course 2 (144 ml/min per 1.73 m2; p = 0.33). The median glomerular filtration rate measured before (159 ml/min per 1.73 m2) and after course 1 (161 ml/min per 1.73 m2) did not differ significantly (p = 0.4). Binding was time dependent but modest with a median free fraction at the end of infusion of 0.82. Pharmacokinetic parameters for continuous‐infusion carboplatin are similar to those reported for short infusions, but the median dose of 817 mg/m2 required to achieve an acceptable systemic exposure in these patients was 45% greater than the previously suggested maximum tolerated dosage. Continuous infusion carboplatin did not alter carboplatin clearance or adversely effect glomerular filtration rate during a second course, showing the feasibility of this alternative dosage strategy to enhance therapeutic effects. Clinical Pharmacology and Therapeutics (1993) 54, 374–380; doi:

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalClinical Pharmacology & Therapeutics
Volume54
Issue number4
DOIs
StatePublished - Oct 1993

Fingerprint

Carboplatin
Pharmacokinetics
Kidney
Glomerular Filtration Rate
Clinical Pharmacology
Therapeutic Uses
Pediatrics
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics and acute renal effects of continuously infused carboplatin. / Murry, Daryl J.; Sandlund, John T.; Stricklin, Lisa M.; Rodman, John H.

In: Clinical Pharmacology & Therapeutics, Vol. 54, No. 4, 10.1993, p. 374-380.

Research output: Contribution to journalArticle

Murry, Daryl J. ; Sandlund, John T. ; Stricklin, Lisa M. ; Rodman, John H. / Pharmacokinetics and acute renal effects of continuously infused carboplatin. In: Clinical Pharmacology & Therapeutics. 1993 ; Vol. 54, No. 4. pp. 374-380.
@article{04e93fbd4ac045df94506e1c5002ba68,
title = "Pharmacokinetics and acute renal effects of continuously infused carboplatin",
abstract = "Carboplatin was given as a 24‐hour infusion at high doses to pediatric patients with cancer (n = 11) and pharmacokinetic parameters and renal effects were determined. Median carboplatin clearance for course 1 (151 ml/min per 1.73 m2;) was not significantly different from clearance for course 2 (144 ml/min per 1.73 m2; p = 0.33). The median glomerular filtration rate measured before (159 ml/min per 1.73 m2) and after course 1 (161 ml/min per 1.73 m2) did not differ significantly (p = 0.4). Binding was time dependent but modest with a median free fraction at the end of infusion of 0.82. Pharmacokinetic parameters for continuous‐infusion carboplatin are similar to those reported for short infusions, but the median dose of 817 mg/m2 required to achieve an acceptable systemic exposure in these patients was 45{\%} greater than the previously suggested maximum tolerated dosage. Continuous infusion carboplatin did not alter carboplatin clearance or adversely effect glomerular filtration rate during a second course, showing the feasibility of this alternative dosage strategy to enhance therapeutic effects. Clinical Pharmacology and Therapeutics (1993) 54, 374–380; doi:",
author = "Murry, {Daryl J.} and Sandlund, {John T.} and Stricklin, {Lisa M.} and Rodman, {John H.}",
year = "1993",
month = "10",
doi = "10.1038/clpt.1993.163",
language = "English (US)",
volume = "54",
pages = "374--380",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and acute renal effects of continuously infused carboplatin

AU - Murry, Daryl J.

AU - Sandlund, John T.

AU - Stricklin, Lisa M.

AU - Rodman, John H.

PY - 1993/10

Y1 - 1993/10

N2 - Carboplatin was given as a 24‐hour infusion at high doses to pediatric patients with cancer (n = 11) and pharmacokinetic parameters and renal effects were determined. Median carboplatin clearance for course 1 (151 ml/min per 1.73 m2;) was not significantly different from clearance for course 2 (144 ml/min per 1.73 m2; p = 0.33). The median glomerular filtration rate measured before (159 ml/min per 1.73 m2) and after course 1 (161 ml/min per 1.73 m2) did not differ significantly (p = 0.4). Binding was time dependent but modest with a median free fraction at the end of infusion of 0.82. Pharmacokinetic parameters for continuous‐infusion carboplatin are similar to those reported for short infusions, but the median dose of 817 mg/m2 required to achieve an acceptable systemic exposure in these patients was 45% greater than the previously suggested maximum tolerated dosage. Continuous infusion carboplatin did not alter carboplatin clearance or adversely effect glomerular filtration rate during a second course, showing the feasibility of this alternative dosage strategy to enhance therapeutic effects. Clinical Pharmacology and Therapeutics (1993) 54, 374–380; doi:

AB - Carboplatin was given as a 24‐hour infusion at high doses to pediatric patients with cancer (n = 11) and pharmacokinetic parameters and renal effects were determined. Median carboplatin clearance for course 1 (151 ml/min per 1.73 m2;) was not significantly different from clearance for course 2 (144 ml/min per 1.73 m2; p = 0.33). The median glomerular filtration rate measured before (159 ml/min per 1.73 m2) and after course 1 (161 ml/min per 1.73 m2) did not differ significantly (p = 0.4). Binding was time dependent but modest with a median free fraction at the end of infusion of 0.82. Pharmacokinetic parameters for continuous‐infusion carboplatin are similar to those reported for short infusions, but the median dose of 817 mg/m2 required to achieve an acceptable systemic exposure in these patients was 45% greater than the previously suggested maximum tolerated dosage. Continuous infusion carboplatin did not alter carboplatin clearance or adversely effect glomerular filtration rate during a second course, showing the feasibility of this alternative dosage strategy to enhance therapeutic effects. Clinical Pharmacology and Therapeutics (1993) 54, 374–380; doi:

UR - http://www.scopus.com/inward/record.url?scp=0027484369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027484369&partnerID=8YFLogxK

U2 - 10.1038/clpt.1993.163

DO - 10.1038/clpt.1993.163

M3 - Article

C2 - 8222479

AN - SCOPUS:0027484369

VL - 54

SP - 374

EP - 380

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -